Vascular Graft Articles & Analysis
21 news found
While countless applications are still being explored, hydrophobic polymers, which are insoluble in water and other polar solvents, are commonly used as coatings, adhesives, fibers, films, and engineering plastics, in addition to biomedical polymers for vascular grafts, implants, and ophthalmic applications. “Our experts are devoted to functionalizing ...
The company, headquartered in Milan, Italy, currently has several assets under development, such as vascular graft, bone graft substitutes, rotator cuff repair, drug release. ...
ByKLISBio
KLISBio is targeting a variety of clinical indications, such as peripheral nerve injuries, peripheral vascular diseases, bone defects, tendon tears and situations where a sustained drug release is needed. ...
ByKLISBio
KLISBio is leveraging silk as a powerful and biocompatible scaffold material, targeting different clinical indications in the orthopedic, vascular and drug release markets via several technology platforms.”, said Jason Schense, CBO and COO. KLISBio is focused on healing and regenerating human body tissues by developing innovative solutions that solve prominent, unmet ...
ByKLISBio
KLISBio is focused on developing innovative solutions that solve prominent unmet clinical needs through a silk-based multidisciplinary technology platform able to generate products and solutions for a variety of clinical indications, such as peripheral nerve injuries, peripheral vascular diseases, bone defects, tendon tears and situations where a sustained drug release is needed. ...
ByKLISBio
The company, headquartered in Milan, Italy, currently has several assets under development, such as vascular graft, bone graft substitutes, rotator cuff repair, drug release. ...
ByKLISBio
“KLISBio is focused on developing innovative solutions to tackle prominent unmet clinical needs through a silk-based multidisciplinary technology platform able to generate products and solutions for a variety of clinical indications, such as peripheral nerve injuries, peripheral vascular diseases, bone defects, tendon tears and situations where a sustained drug release is ...
ByKLISBio
Among the company’s developing portfolio of products is SILKBridge®, a first-to-market, silk-based graft for peripheral nerve repair, which is anticipated to be available for clinical use in 2023. ...
ByKLISBio
KLISBio will introduce SILKBridge® to attendees at the American Association for Hand Surgeons Annual Meeting Jan. 12-15, 2022. SILKBridge®, a silk-based graft, is a tissue-engineered technology based on pure silk fibroin. ...
ByKLISBio
Engineered silk materials provide a unique combination of outstanding biological and mechanical properties for a variety of clinical indications such as peripheral nerve injuries, peripheral vascular diseases, bone defects, tendon tears and situations where a sustained drug release is needed. ...
ByKLISBio
” Xeltis’ devices are vascular grafts and heart valves designed to turn into living valves and vessels by harnessing the body’s natural healing process and by facilitating tissue formation once implanted. ...
In addition to its restorative pulmonary valve, Xeltis has developed the first-ever restorative synthetic coronary artery bypass graft (CABG) to have shown successful long-term results in long preclinical trials and the first-ever restorative synthetic vascular access graft for patients that need ...
Healionics is preparing to commercialize its innovative STARgraft vascular graft, designed to provide a safer and more reliable means to access the bloodstream for dialysis in patients with kidney failure. ...
The financing supports the first human study, currently underway, of the company's innovative STARgraft vascular graft. In preclinical studies, STARgraft demonstrated improved ability to maintain blood flow compared to on-market vascular grafts, thereby offering the potential to reduce cost and morbidity while improving quality ...
” While Invizius’s first product is aimed at kidney dialysis, there is also potential to use the technology with other devices or procedures such as cardiopulmonary bypass, catheters, stents, organ transplants and vascular grafts. The company stems from years of research by Invizius’s co-founder and CTO, Dr Andy Herbert and his team while ...
” Said Takeuchi, “Healionics’ STARgraft and related future products have the potential to reduce the huge costs associated with maintaining reliable vascular access for dialysis patients and to improve the health and quality of life of these patients. ...
While the first product is aimed at kidney dialysis, there is also potential to use the technology with other devices or procedures such as catheters, stents, organ transplants and vascular grafts. Invizius is led by CEO and co-founder Richard Boyd, who previously founded VueKlar Cardiovascular, with Dr Herbert as CTO. ...
The clinical study will evaluate STARgraft as a vascular access graft for dialysis patients and will be conducted in collaboration with University of Washington Medicine. ...
Healionics Corporation, a Seattle-based medical device company, was awarded a $1.5M Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) to develop new vascular grafts for dialysis use that overcome the major problem of clotting ...
Healionics Corporation has been awarded a $150,000 Small Business Innovation Research (SBIR) contract from the Department of Defense (DOD) to demonstrate feasibility for an improved vascular graft design. Andrew Marshall, PhD, Healionics’ Chief Technology Officer, is the Principal Investigator for this research project. Titled, “Biointegrated ...